Boothbay Fund Management’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q4 | – | Sell |
-848,800
| Closed | -$15.7M | – | 2126 |
|
|
2023
Q3 | $15.7M | Buy |
848,800
+2,100
| +0.2% | +$23.8K | 0.37% | 41 |
|
|
2023
Q2 | $9.36M | Buy |
+846,700
| New | +$11.8M | 0.21% | 85 |
|
|
2022
Q1 | – | Sell |
-183,600
| Closed | -$2.99M | – | 2630 |
|
|
2021
Q4 | $2.99M | Buy |
183,600
+137,300
| +297% | +$2.31M | 0.07% | 347 |
|
|
2021
Q3 | $688K | Buy |
+46,300
| New | +$741K | 0.02% | 939 |
|
|
2020
Q3 | – | Sell |
-281
| Closed | -$1.35M | – | 1287 |
|
|
2020
Q2 | $1.35M | Sell |
281
-201
| -42% | -$15.5K | 0.09% | 297 |
|
|
2020
Q1 | $3.04M | Sell |
482
-740
| -61% | -$66.5K | 0.25% | 95 |
|
|
2019
Q4 | $15.1M | Buy |
1,222
+597
| +96% | +$53.4K | 1.32% | 3 |
|
|
2019
Q3 | $4.15M | Buy |
+625
| New | +$42K | 0.38% | 48 |
|
|
2019
Q2 | – | Sell |
-496
| Closed | -$5.55M | – | 941 |
|
|
2019
Q1 | $5.55M | Buy |
+496
| New | +$54.2K | 0.54% | 33 |
|
|
2016
Q2 | – | Sell |
-16,600
| Closed | -$2.13M | – | 613 |
|
|
2016
Q1 | $2.13M | Buy |
+16,600
| New | +$1.96M | 1.59% | 4 |
|
Boothbay Fund Management's ICPT Position: Q3 2023 in Review
Boothbay Fund Management sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q3 2023, closing a stake of 941,755 shares — an estimated $10.7M sold.
Boothbay Fund Management first reported a position in ICPT in Q4 2021 and held it in 6 quarters. The position peaked at $10.4M in Q2 2023. 146 funds tracked by Wall St. Rank hold ICPT as of Q3 2023.
- Boothbay Fund Management reported no remaining Intercept Pharmaceuticals, Inc. position as of Q3 2023 after selling out during the quarter.
- Boothbay Fund Management sold 941,755 Intercept Pharmaceuticals, Inc. shares in Q3 2023, an estimated $10.7M.
- Boothbay Fund Management first reported a position in Intercept Pharmaceuticals, Inc. in Q4 2021 and held it in 6 quarters.
- Boothbay Fund Management's Intercept Pharmaceuticals, Inc. position peaked at $10.4M in Q2 2023.
- 146 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q3 2023.
Based on Boothbay Fund Management's 13F filing for Q3 2023, filed 14 Nov 2023.